These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

376 related articles for article (PubMed ID: 21843173)

  • 1. Dual-time-point (18)F-FDG-PET/CT imaging in the assessment of suspected malignancy.
    Chan WL; Ramsay SC; Szeto ER; Freund J; Pohlen JM; Tarlinton LC; Young A; Hickey A; Dura R
    J Med Imaging Radiat Oncol; 2011 Aug; 55(4):379-90. PubMed ID: 21843173
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Dual-time-point FDG PET/CT for the evaluation of pediatric tumors.
    Costantini DL; Vali R; Chan J; McQuattie S; Charron M
    AJR Am J Roentgenol; 2013 Feb; 200(2):408-13. PubMed ID: 23345365
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Value of dual-time-point (18)F-fluorodeoxyglucose integrated positron emission and computed tomography in differentiation of malignant from benign gastrointestinal diseases].
    Xu XX; Cheng J; Xu WG; Dai D; Song XY; Ma WC; Zhu L; Zhu X
    Zhonghua Zhong Liu Za Zhi; 2012 May; 34(5):364-8. PubMed ID: 22883458
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The value of dual time point (18)F-FDG PET imaging for the differentiation between malignant and benign lesions.
    Lan XL; Zhang YX; Wu ZJ; Jia Q; Wei H; Gao ZR
    Clin Radiol; 2008 Jul; 63(7):756-64. PubMed ID: 18555033
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Dual-time-point 18F-FDG PET for the evaluation of gallbladder carcinoma.
    Nishiyama Y; Yamamoto Y; Fukunaga K; Kimura N; Miki A; Sasakawa Y; Wakabayashi H; Satoh K; Ohkawa M
    J Nucl Med; 2006 Apr; 47(4):633-8. PubMed ID: 16595497
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Clinical impact of "true whole-body" (18)F-FDG PET/CT: lesion frequency and added benefit in distal lower extremities.
    Kawata S; Imaizumi M; Kako Y; Oku N
    Ann Nucl Med; 2014 May; 28(4):322-8. PubMed ID: 24488705
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Role of delayed-time-point imaging during abdominal and pelvic cancer screening using FDG-PET/CT in the general population.
    Naganawa S; Yoshikawa T; Yasaka K; Maeda E; Hayashi N; Abe O
    Medicine (Baltimore); 2017 Nov; 96(46):e8832. PubMed ID: 29145346
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Assessment of combination of contrast-enhanced magnetic resonance imaging and positron emission tomography/computed tomography for evaluation of ovarian masses.
    Tsuboyama T; Tatsumi M; Onishi H; Nakamoto A; Kim T; Hori M; Sakane M; Hori Y; Morii E; Hatazawa J; Tomiyama N
    Invest Radiol; 2014 Aug; 49(8):524-31. PubMed ID: 24637584
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Dual-time point
    Parghane RV; Basu S
    Semin Nucl Med; 2017 Jul; 47(4):373-391. PubMed ID: 28583277
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Performance of whole-body integrated 18F-FDG PET/MR in comparison to PET/CT for evaluation of malignant bone lesions.
    Eiber M; Takei T; Souvatzoglou M; Mayerhoefer ME; Fürst S; Gaertner FC; Loeffelbein DJ; Rummeny EJ; Ziegler SI; Schwaiger M; Beer AJ
    J Nucl Med; 2014 Feb; 55(2):191-7. PubMed ID: 24309383
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Analysis of incidental focal hypermetabolic uptake in the breast as detected by 18F-FDG PET/CT: clinical significance and differential diagnosis.
    Chae EY; Cha JH; Kim HH; Shin HJ; Kim HJ; Oh HY; Koh YH; Moon DH
    Acta Radiol; 2012 Jun; 53(5):530-5. PubMed ID: 22593124
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Dual-time point images of the liver with (18)F-FDG PET/CT in suspected recurrence from colorectal cancer].
    Fuster D; Lafuente S; Setoain X; Navales I; Perissinotti A; Pavia J; Paredes P; Lomeña F; Pons F
    Rev Esp Med Nucl Imagen Mol; 2012; 31(3):111-6. PubMed ID: 22154291
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Diagnosis of metastases from postoperative differentiated thyroid cancer: comparison between FDG and FLT PET/CT studies.
    Nakajo M; Nakajo M; Jinguji M; Tani A; Kajiya Y; Tanabe H; Fukukura Y; Nakabeppu Y; Koriyama C
    Radiology; 2013 Jun; 267(3):891-901. PubMed ID: 23468571
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The clinical value of dual-time point 18F-FDG PET/CT for differentiating extrahepatic cholangiocarcinoma from benign disease.
    Choi EK; Yoo IeR; Kim SH; O JH; Choi WH; Na SJ; Park SY
    Clin Nucl Med; 2013 Mar; 38(3):e106-11. PubMed ID: 23354026
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Dual-time point 18FDG-PET/CT imaging may be useful in assessing local recurrent disease in high grade bone and soft tissue sarcoma.
    Dancheva Z; Bochev P; Chaushev B; Yordanova T; Klisarova A
    Nucl Med Rev Cent East Eur; 2016; 19(1):22-7. PubMed ID: 26841376
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Role of (18)F-fluorodeoxyglucose positron emission tomography/computed tomography in the characterization of pancreatic masses: experience from tropics.
    Santhosh S; Mittal BR; Bhasin D; Srinivasan R; Rana S; Das A; Nada R; Bhattacharya A; Gupta R; Kapoor R
    J Gastroenterol Hepatol; 2013 Feb; 28(2):255-61. PubMed ID: 23278193
    [TBL] [Abstract][Full Text] [Related]  

  • 17. 18F-FDG PET/CT qualitative and quantitative evaluation in neurofibromatosis type 1 patients for detection of malignant transformation: comparison of early to delayed imaging with and without liver activity normalization.
    Chirindel A; Chaudhry M; Blakeley JO; Wahl R
    J Nucl Med; 2015 Mar; 56(3):379-85. PubMed ID: 25655626
    [TBL] [Abstract][Full Text] [Related]  

  • 18. ¹¹C-methionine and ¹⁸F-fluorodeoxyglucose positron emission tomography/CT in the evaluation of patients with suspected primary and residual/recurrent gliomas.
    Li DL; Xu YK; Wang QS; Wu HB; Li HS
    Chin Med J (Engl); 2012 Jan; 125(1):91-6. PubMed ID: 22340472
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Dual time point 2-deoxy-2-[18F]fluoro-D-glucose PET/CT: nodal staging in locally advanced breast cancer.
    García Vicente AM; Soriano Castrejón A; Cruz Mora MÁ; Ortega Ruiperez C; Espinosa Aunión R; León Martín A; González Ageitos A; Van Gómez López O
    Rev Esp Med Nucl Imagen Mol; 2014; 33(1):1-5. PubMed ID: 23707190
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Evaluation of soft-tissue lesions with (18)F-FDG PET/CT: initial results of a prospective trial.
    Leal AL; Etchebehere M; Santos AO; Kalaf G; Pacheco EB; Amstalden EM; Etchebehere EC
    Nucl Med Commun; 2014 Mar; 35(3):252-9. PubMed ID: 24300379
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 19.